Open Orphan sets sights on €100m valuation
Open Orphan is targeting a valuation of €100 million in the next year after it completes the reverse takeover of drug services company Venn Life Sciences.
Open Orphan is currently in the middle of a fundraising round with the company seeking a modest amount of new cash, understood to be less than €10 million, from investors, according to market sources. The company and its advisers, IBI Corporate Finance, met with potential new investors in London last...
Subscribe from just 1€
Choose the subscription that is right for you
For the first month
€19.99 Monthly ThereafterSubscribe today
For the first year
€199.99 annually thereafterSubscribe today
For the first 90 days
€55.00 quarterly ThereafterSubscribe today
These offers are not available for current subscribers. Offers and pricing are subject to change without notice.
Terms & Conditions Apply